Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate and High-dose Vitamin D in Mexican Postmenopausal Women
NCT05346419Completed
- Sponsor
- Hospital Regional 1° de Octubre
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Open-label, single-arm trial of risedronate and vitamin d in postmenopausal osteoporosis, osteopenia, hyperparathyroidism and 1 more, sponsored by Hospital Regional 1° de Octubre. Primary endpoints: Remission of hyperparathyroidism at 6 months, Remission of hypovitaminosis D at 6 months and 2 more. Started Jul 2021; status: completed.
02
Drugs
risedronatevitamin d
03
Conditions
postmenopausal osteoporosisosteopeniahyperparathyroidismvitamin D deficiency
Beyond the preview
Go deeper on NCT05346419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346419.